Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia

Giuseppe Saglio • 12 Jun 2015
EHA 2015
Chronic Myeloid Leukemia Dasatinib Imatinib Nilotinib Ponatinib

At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the latest clinical trial results of tyrosine kinase inhibitors (TKIs) for the treatment of patients with chronic myeloid leukemia. As therapeutic strategies with TKIs continue to improve patient outcomes, the importance of monitoring and optimally managing patients is emphasized.

More from Giuseppe Saglio

Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
1:04
Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
Giuseppe Saglio • 5 Mar 2025
Factors affecting adherence to TKI therapy in patients with CML
1:52
Factors affecting adherence to TKI therapy in patients with CML
Giuseppe Saglio • 5 Mar 2025
The use of asciminib in the frontline treatment of CML
4:12
The use of asciminib in the frontline treatment of CML
Giuseppe Saglio • 5 Mar 2025
Commonly observed side effects with asciminib and how to manage them
1:29
Commonly observed side effects with asciminib and how to manage them
Giuseppe Saglio • 5 Mar 2025

Related Videos

Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
Beyond the label: optimal dosing strategies for CML in community practice
0:51
Beyond the label: optimal dosing strategies for CML in community practice
Fadi Haddad • 10 Sep 2026
Incorporating patient goals into frontline TKI selection in CML
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
Optimizing frontline therapy selection to prevent resistance in CML
1:58
Optimizing frontline therapy selection to prevent resistance in CML
Jorge Cortes • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals